AACR cancer progress report 2013

Clinical Cancer Research

Volumn 19, Issue SUPPL.1, 2013, Pages

  Sawyers, Charles L ^a   Abate Shen, Cory ^b   Anderson, Kenneth C ^c   Barker, Anna ^d   Baselga, José ^a   Berger, Nathan A ^e   Foti, Margaret ^f   Jemal, Ahmedin ^g   Lawrence, Theodore S ^h   Li, Christopher I ⁱ   Mardis, Elaine R ^j   Neumann, Peter J ^k   Pardoll, Drew M ^l   Prendergast, George C ^m   Reed, John C ⁿ   Weiner, George J ^o  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Medicine   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f American Association for Cancer Research   (United States)

^g AMERICAN CANCER SOCIETY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ USA   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k TUFTS MEDICAL CENTER   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

^o UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRICIL; AFATINIB; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BOSUTINIB; CABOZANTINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; DENOSUMAB; FLUOROURACIL; HOMOHARRINGTONINE; IMATINIB; INCLUSIG; INGENOL MEBUTATE; LENALIDOMIDE; METFORMIN; NILOTINIB; PACLITAXEL; PAZOPANIB; POMALIDOMIDE; PONATINIB; RADIUM CHLORIDE RA 223; REGORAFENIB; SORAFENIB; SUNITINIB; TILMANOCEPT TC 99M; TRAMETINIB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ACTINIC KERATOSIS; ANTIANGIOGENIC THERAPY; ANUS CANCER; ARTICLE; BONE CANCER; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVOR; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLONORCHIS SINENSIS; COLON CANCER; COLORECTAL CANCER; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSIS; DNA METHYLATION; EARLY DIAGNOSIS; ECONOMICS; ENERGY BALANCE; EPIGENETICS; EPSTEIN BARR VIRUS; FEMALE; FINANCIAL MANAGEMENT; FUNDING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC RISK; GENOMICS; HEALTH CARE ORGANIZATION; HEALTH DISPARITY; HELICOBACTER PYLORI; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HISTONE ACETYLATION; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; INFLAMMATORY BREAST CANCER; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MEDICAL RESEARCH; MELANOMA; MERKEL CELL POLYOMAVIRUS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NANOMEDICINE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPISTHORCHIS VIVERRINI; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PATIENT PARTICIPATION; PHYSICAL ACTIVITY; PRECANCER; PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTO ONCOGENE; RADIATION DOSE; RESEARCH; SCHISTOSOMA HEMATOBIUM; SMOKING; SOFT TISSUE SARCOMA; SOLID TUMOR; STATISTICS; SURVIVAL RATE; TESTIS CANCER; THERAPY; THYROID CANCER; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ULTRASOUND SCANNER; ULTRAVIOLET RADIATION; UNITED STATES; UTERUS CANCER; WART VIRUS;

BIOMEDICAL RESEARCH; DIAGNOSIS; EARLY DETECTION OF CANCER; ECONOMICS; FEMALE; FINANCING, GOVERNMENT; HUMANS; MALE; METHODS; NEOPLASMS; PREVENTION AND CONTROL; RESEARCH REPORT; RESEARCH SUPPORT AS TOPIC; SOCIETIES, SCIENTIFIC; STATISTICS AND NUMERICAL DATA; THERAPY; TRENDS; UNITED STATES;

EID: 84887101903     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2107     Document Type: Article

References (182)

1. American Cancer Society. Cancer facts and figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Desantis C, Siegel R, Jemal A. Cancer treatment and survivorship facts and figures 2012-2013. Atlanta, GA: American Cancer Society; 2012.
3. Cancer survivorship - United States, 1971-2001. MMWR Morb Mortal Wkly Rep 2004;53: 526-9.
4. Howlander N, Noone AM, Krapcho M, Neyman N, Aminou R, Alterkuse SF, et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations). Bethesda, MD: National Institutes of Health; 2012.
5. American Cancer Society. Cancer facts and figures for Hispanics/Latinos 2012-2014. Atlanta, GA: American Cancer Society; 2012.
6. U.S. Census. Age and sex composition: 2010. [cited 2013 July 31]. Available from: http://www.census.gov/prod/cen2010/briefs/cbr-03.pdf%5D.
7. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. Journal Clin Oncol 2009;27: 2758-65.
8. World Cancer Research Fund. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007.
9. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet 2009;10: 1033-4.
10. Colditz GA, Wei EK. Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. Annu Rev Public Health 2012;33: 137-56.
11. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a populationbased study. Lancet Oncol 2012;13: 790-801.
12. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-917.
13. American Cancer Society and LIVESTRONG. The global economic cost of cancer. American Cancer Society: Atlanta, GA; 2010.
14. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140: 883-99.
15. Wellmann KF. [Smoking and Health. On the Report of the Advisory Committee to the Surgeon General of the Public Health Service] [article in German]. Dtsch Med Wochenschr 1964;89: 1085-6.
16. Centers for Diesease Control and Prevention. Trends in current cigarette smoking among high school students and adults, United States, 1965-2011. 2012 [cited 2013 May 15]; Available from: http://www.cdc.gov/tobacco/data-statistics/ tables/trends/cig-smoking/
17. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
18. U.S. Department of Health and Human Services. Women and smoking: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Office on Smoking and Health; 2001.
19. U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2010.
20. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-Century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368: 341-50.
21. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-Year trends in smoking-related mortality in the United States. N Engl J Med 2013;368: 351-64.
22. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens - Part D: radiation. Lancet Oncol 2009;10: 751-2.
23. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29: 257-63.
24. Zhang M, Qureshi AA, Geller AC, Frazier L, Hunter DJ, Han J. Use of tanning beds and incidence of skin cancer. J Clin Oncol 2012;30: 1588-93.
25. Lazovich D, Vogel RI, Berwick M, Weinstock MA, Anderson KE, Warshaw EM. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 19: 1557-68.
26. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012;345:e4757.
27. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012;61: 1-162.
28. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103: 117-28.
29. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10: 321-2.
30. Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012;7: 123-44.
31. Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy 2011;31: 280-97.
32. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13: 607-15.
33. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12: 663-72.
34. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
35. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62: 591-5.
36. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208: 385-93.
37. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep 2011;60: 1117-23.
38. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007;67: 10618-22.
39. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotatingshift workers: findings from the Japan Collaborative Cohort Study. Am J Epidemiol 2006;164: 549-55.
40. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001;93: 1563-8.
41. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. J Natl Cancer Inst 2003;95: 825-8.
42. Jiao L, Duan Z, Sangi-Haghpeykar H, Hale L, White DL, El-Serag HB. Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 2013;108: 213-21.
43. Luo J, Sands M, Wactawski-Wende J, Song Y, Margolis KL. Sleep disturbance and incidence of thyroid cancer in postmenopausal women: The Women's Health Initiative. Am J Epidemiol 2013;177: 42-9.
44. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farré R. Sleep-disordered breathing and cancer mortality. Am J Respir Crit Care Med 2012;186: 190-4.
45. Boyko EJ, Seelig AD, Jacobson IG, Hooper TI, Smith B, Smith TC, et al. Sleep characteristics, mental health, and diabetes risk: A prospective study of U.S. military service members in the Millennium Cohort Study. Diabetes Care 2013 Jul 8. [Epub ahead of print].
46. Nock NL, Berger NA. Obesity and cancer, overview and mechanisms. In: Berger NA, editor. Cancer and energy balance, epidemiology and overview. Energy balance and cancer, volume 2. New York: Springer; 2010. p. 129-79.
47. Kondratov RV, Antoch MP. Circadian proteins in the regulation of cell cycle and genotoxic stress responses. Trends Cell Biol 2007;17: 311-7.
48. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 2009;13: 257-64.
49. Kang TH, Sancar A. Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy. Cell Cycle 2009;8: 1665-7.
50. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci U S A 2009;106: 2864-7.
51. Berger NA, editor. Energy balance and cancer. New York: Springer; 2010.
52. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark- Wahnefried W, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) 2012;5: 1260-72.
53. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348: 1625-38.
54. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone A-M, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118: 2338-66.
55. Dannenberg AJ, Berger NA. Obesity, inflammation and cancer: new opportunities for prevention. Cancer Prev Res (Phila) 2012;5: 1260-72.
56. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012 Jan;(82): 1-8.
57. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12: 236-44.
58. Habib SL, Rojna M. Diabetes and Risk of Cancer. ISRN Oncol 2013;2013: 16.
59. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and Cancer: A Consensus Report. CA Cancer J Clin 2010;60: 207-21.
60. Jeon JY, Jeong DH, Park MG, Lee J-W, Chu SH, Park J-H, et al. Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer. PLoS ONE. 2013;8:e55196.
61. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. [cited 2013 July 31]; Available from: http://www.cdc.gov/diabetes/pubs/ factsheet11.htm
62. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: 1766-77.
63. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012;51: 64-74.
64. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013 Jun 14. [Epub ahead of print].
65. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, GALVÃO DA, Pinto BM, et al. American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors. Med Sci Sports Exerc. 2010;42: 1409-26.
66. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012;62: 242-74.
67. Boyle T, Fritschi L, Heyworth J, Bull F. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol 2011;173: 1183-91.
68. Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol 2013;31: 876-85.
69. Patel AV, Bernstein L, Deka A, Feigelson HS, Campbell PT, Gapstur SM, et al. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol 2010;172: 419-29.
70. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24: 3527-34.
71. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012;104: 815-40.
72. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and niochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4: 486-501.
73. Irwin ML. Benefits of aerobic and resistance exercise for cancer survivors. In: Ulrich CM, et al., editors. Exercise, energy balance, and cancer. Energy balance and cancer, vol. 6. New York: Springer; 2013 p. 199-213.
74. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011;4: 53-61.
75. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370: 59-67.
76. Laara E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987;1: 1247-9.
77. Cervical Cancer. [cited 2012 August 31]; Available from: http://www.cancer. org/Cancer/CervicalCancer/DetailedGuide/cervical-cancer-key- statistics
78. Centers for Disease Control and Prevention. Cancer screening - United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61: 41-5.
79. Vital signs: Colorectal cancer screening, incidence, and mortality - United States, 2002-2010. MMWR Morb Mortal Wkly Rep 2011;60: 884-9.
80. Siegel R, Jemal A. Colorectal cancer facts & Figures, 2011-2013. Atlanta, GA: American Cancer Society; 2011.
81. Grubbs SS, Polite BN, Carney J Jr, Bowser W, Rogers J, Katurakes N, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol 2013;31: 1928-30.
82. U.S. Census Bureau. 2008 National Population Projections: Table 4 Projections of the Population by Sex, Race, and Hispanic Origin for the United States: 2010 to 2050. 2008 National Population Projections: Summary Tables. 2008 [cited 2013 July 31]; Available from: http://www. census.gov/population/ projections/data/national/2008/summarytables.html
83. Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: Did the gap narrow between 1992 and 2002? Cancer 2008;112: 900-8.
84. American Cancer Society. Cancer facts and figures for African Americans 2013-2014. Atlanta, GA: American Cancer Society; 2013.
85. Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, et al. European ancestry is positively associated with breast cancer risk in Mexican Women. Cancer Epidemiol Biomarkers Prev 2010;19: 1074-82.
86. Maskarinec G, Noh JJ. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn Dis 2004;14: 431-9.
87. Kaiser Family Foundation. Health coverage by race and ethnicity: the potentialimpact of the Affordable Care Act. Washington, DC: Kaiser Family Foundation; 2013.
88. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013;10: 38-48.
89. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190: 419-26.
90. Bleyer A, Welch HG. Effect of three decades of screening mammography onbreast-cancer incidence. N Engl J Med 2012;367: 1998-2005.
91. National Lung Screening Trial Research Team. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368: 1980-91.
92. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365: 395-409.
93. Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012;157: 571-3.
94. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns - getting past uninformative persuasion. N Engl J Med 2012;367: 1677-9.
95. National Cancer Institute. Cancer survivorship research. [cited 2013 July 31]; Available from: http://cancercontrol.cancer.gov/ocs/
96. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353: 2747-57.
97. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al., for the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365: 60-2.
98. Early Breast Cancer Trialists' Collaborative Group, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet 2011;378: 771-84.
99. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381: 805-16.
100. Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31: 5, 2013 (suppl).
101. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367: 1596-606.
102. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302: 649-58.
103. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348: 883-90.
104. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369: 213-23.
105. Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012;13: 1129-32.
106. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improvedsurvival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
107. Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24: 2174-80.
108. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination withpaclitaxel and carboplatin as first-line treatment instage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, Multicenter Phase II Study. Journal of Clinical Oncology. 2012;30: 2046-54.
109. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24: 1813-21.
110. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-54.
111. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of ati-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-65.
112. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013;19: 462-8.
113. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2013;31: 8030.
114. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134-44.
115. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369: 122-33.
116. Hodi FS, Lee SJ, McDermott DF, Rao UNM, Butterfield LH, Tarhini AA, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013;31:CRA9007.
117. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363: 411-22.
118. Small EJ, Lance RS, Redfern CH, Millard FE, Gardner TA, Karsh LI, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 31, 2013 (suppl; abstr 5047).
119. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013 May 7. [Epub ahead of print].
120. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA - targeted immunotherapy in metastaticcastrationresistant prostatecancer. J Clin Oncol 2010;28: 1099-105.
121. Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Springett GM, et al. Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4040).
122. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Transl Med 2011;3: 95ra73.
123. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor- transduced T cells. Blood 2012;119: 2709-20.
124. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science Transl Med 2013;5: 177ra38.
125. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368: 1509-18.
126. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25: 13-25.
127. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6: 443-6.
128. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115: 4393-402.
129. Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, Tilly H, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2012;119: 5126-32.
130. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119: 5126-32.
131. Goede V, Fischer K, Humphrey K, Asikanius E, Busch R, Engelke A, et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial. J Clin Oncol 31, 2013 (suppl; abstr 7004).
132. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367: 1783-91.
133. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
134. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355: 2733-43.
135. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366: 109-19.
136. U.S. Food and Drug Administration. Cabozantinib. 2012 [cited 2013 July 31]; Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm330213.htm
137. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381: 303-12.
138. Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381: 295-302.
139. Du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol 31, 2013 (suppl; abstr LBA5503).
140. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 31, 2013 (suppl; abstr 4)
141. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther 2013;6: 531-8.
142. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27: 5008-14.
143. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-17.
144. U.S. Food and Drug Administration. Bosutinib tablets. 2012 [cited 2013 July 31]; Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm318203.htm.
145. Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120: 2573-80.
146. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367: 2075-88.
147. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364: 2507-16.
148. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380: 358-65.
149. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367: 107-14.
150. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367: 1694-703.
151. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Jul 1. 2013 [Epub ahead of print].
152. Thomas DM, Skubitz KM. Giant cell tumour of bone. Current Opin Oncol 2009;21: 338-44.
153. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012;18: 4415-24.
154. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatinversus solvent-based paclitaxel plus carboplatin as first-line therapy inpatients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30: 2055-62.
155. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic
156. Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, et al. Comparative evaluation of [99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. Ann Surg Oncol 2013;20: 2590-9.
157. Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, et al. Combined analysis of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identification ofsentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol 2013;20: 680-8.
158. Board on Radiation Effects Research, Division on Earth and Life Studies, National Research Council of the National Academies. Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press; 2006.
159. Brenner DJ, Hall EJ. Computed tomography - an increasing source of radiation exposure. N Engl J Med 2007;357: 2277-84.
160. IMV. CT market summary report. Des Plains, IL: IMV Medical Division; 2006.
161. IMV. CT market outlook. Des Plains, IL: IMV Medical Division; 2012.
162. Miglioretti DL, Johnson E, Williams A, Greenlee RT, Weinmann S, Solberg LI, et al. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr 2013 June 10. [Epub ahead of print].
163. Chen MY, Shanbhag SM, Arai AE. Submillisievert median radiation dose for coronary angiography with a second-generation 320-detectorrow CT scanner in 107 consecutive patients. Radiology 2013;267: 76-85.
164. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356: 227-36.
165. Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts. Clin Imaging. 2013;37: 480-6.
166. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer Genome Landscapes. Science. 2013;339: 1546-58.
167. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-97.
168. Ross JS, Cristofanilli M, Downing S, Yelensky R, Lipson D, Otto G, et al. Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 1009).
169. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3: 224-37.
170. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338: 221.
171. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10: 1311-6.
172. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011;10: 3-8.
173. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program: The National Academies Press; 2010.
174. National Institutes of Health. Statement of commitment to new and early stage investigators. [cited 2013 June 16]; Available from: http://grants.nih. gov/grants/new-investigators/.
175. National Institutes of Health. Draft report of the Advisory Committee to the Director Working Group on Diversity in the Biomedical Research Workforce. Bethesda, MD: The National Institutes of Health; 2012.
176. National Institutes of Health. About the NIH. [cited 2013 July 31]; Available from: http://www.nih.gov/about/
177. National Institutes of Health. Our Reserch. [cited 2013 July 31]; Available from: http://irp.nih.gov/our-research/principal-investigators
178. National Institutes of Health. NIH Budget. [cited 2013 July 31]; Available from: http://www.nih.gov/about/budget.htm
179. National Institutes of Health. Impact of NIH Research. [cited 2013 July 31]; Available from: http://www.nih.gov/about/impact/
180. Ehrlich EM. An economic engine - NIH research, employment, and the future of the medical innovation sector. Washington, DC: United for Medical Research; 2011.
181. Wolff E. Profiles of prosperity. Washingtion, DC: United for Medical Research; 2013.
182. Atkinson RD, Ezell SJ, Giddings LV, Stewart LA, Andes SM. Leadership in decline: Assessing U.S. international competitiveness in biomedical research. Washington, DC: The Information Technology and Innovation Foundation and United for Medical Research; 2012.